Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(54)
•••
Comment by HarveyTwofaceon Apr 21, 2018 8:41am
158 Views
Post# 27921211

RE:WOW ATE TARGET 1.40 !!!!

RE:WOW ATE TARGET 1.40 !!!!https://www.cantechletter.com/2018/04/antibe-therapeutics-has-a-192-per-cent-upside-echelon-wealth-says/

Kind of laughably low valuation from this guy. Probably did not do his homework properly.

Sure, maybe 1.40 CAD is enough within a year with only a "smaller deal" such as Japan/Asia (not US and EU market deals),

Also may be correct valuation after next phase 2 efficacy results coming in Q4, (still low valuation) - but thinking this will be the value during or after the phase 3 ?!? Yeah, sure, I want the same sh*t this guy is smoking...!

Considering the patent cliff, and how phase 1/2 research companies gets bought for 100s of millions, and considering the huge market for NSAIDs (at least 12-13 billion USD per year), and that a superior NSAID could well reach record sales figures - you are almost bashing the sp when giving a conservative target price like this guy did...
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities